Related Experiment Video
Updated: Oct 7, 2025
Digestion of Whole Mouse Eyes for Multi-Parameter Flow Cytometric Analysis of Mononuclear Phagocytes
Published on: June 17, 2020
Complement cascade inhibition in geographic atrophy: a review
Dhaval Desai1, Pravin U Dugel2
1Iveric Bio, 1249 South River Road, Suite 107, Cranbury, NJ, 08512, USA.
Insights
Dry age-related macular degeneration (AMD) and geographic atrophy (GA) involve the complement cascade. Targeting complement proteins like C3, C5, and complement factors (CFB, CFD, CFH, CFI) offers potential therapeutic strategies for GA.
Area of Science:
- Immunology
- Ophthalmology
Background:
- Dry age-related macular degeneration (AMD) with geographic atrophy (GA) is linked to the complement cascade, a key part of the innate immune system.
- The complement system comprises classical, alternative, and lectin pathways involving plasma and membrane-associated proteins activated by non-self entities.
Purpose of the Study:
- To explore the role of the complement cascade in the pathophysiology of dry AMD and GA.
- To identify complement proteins and factors as potential therapeutic targets for GA treatment.
Main Methods:
- Review of scientific literature on complement pathways and their involvement in dry AMD.
- Analysis of complement proteins (C3, C5) and factors (CFB, CFD, CFH, CFI) as therapeutic targets.
Main Results:
- The convergence of complement pathways at C3 and C5 highlights their significance in dry AMD progression.
- Several complement factors (CFB, CFD, CFH, CFI) are implicated and represent viable therapeutic targets.
Conclusions:
- Complement-directed therapeutics are under investigation for dry AMD treatment.
- The development of the first approved treatment for GA may emerge from these complement-targeted approaches.
Abstract:
The pathophysiology of dry age-related macular degeneration (AMD) and specifically geographic atrophy (GA) has been linked to the complement cascade. This cascade is part of the innate immune system and is made up of the classical, alternative, and lectin pathways. The pathways comprise a system of plasma and membrane-associated serum proteins that are activated with identification of a nonself entity. A number of these proteins have been implicated in the development and progression of dry AMD. The three pathways converge at C3 and cascade down through C5, making both of these proteins viable targets for the treatment of dry AMD. In addition, there are a number of complement factors, CFB, CFD, CFH, and CFI, which are potential therapeutic targets as well. Several different complement-directed therapeutics are being studied for the treatment of dry AMD with the hope that one of these approaches will emerge as the first approved treatment for GA.
